ITOS Valuation

Iteos Therapeutics Inc

Add to Watchlist

Advanced Chart

10.260

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

ITOS Relative Valuation

ITOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ITOS is overvalued; if below, it's undervalued.

Historical Valuation

Iteos Therapeutics Inc (ITOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -63.97. The fair price of Iteos Therapeutics Inc (ITOS) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：10.26

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.70

P/B

Median3y

0.77

Median5y

1.45

-25.55

FCF Yield

Median3y

-21.72

Median5y

-5.46

Competitors Valuation Multiple

The average P/S ratio for ITOS's competitors is 5.60, providing a benchmark for relative valuation. Iteos Therapeutics Inc Corp (ITOS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ITOS.O

Iteos Therapeutics Inc

Loss

Average P/S: 5.60

392.69M